Zoetis (ZTS) Q2 2022 Earnings Call Transcript

Zoetis (ZTS -0.66%)
Q2 2022 Earnings Call
Aug 04, 2022, 8:00 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Welcome to the second quarter 2022 financial results conference call and webcast for Zoetis. Hosting the call today is Steve Frank, vice president of investor relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. Presentation slides can be managed by you, the viewer, and will not be forwarded automatically.

In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. [Operator instructions] It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.

Steve Frank -- Vice President, Investor Relations

Thank you. Good morning, everyone, and welcome to the Zoetis second quarter 2022 earnings call. I am joined today by Kristin Peck, our chief executive officer; and Wetteny Joseph, our chief financial officer. Before we begin, I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks today will include forward-looking statements.

And that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and our SEC filings, including, but not limited to, our annual report on Form 10-K and our reports on Form 10-Q. Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U.S. GAAP.

A reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures is included in the financial tables that accompany our earnings press release and the company's 8-K filing dated today, Thursday, August 4th, 2022. We also cite operational results, which exclude the impact of foreign exchange. With that, I will turn the call over to Kristin.

Kristin Peck -- Chief Executive Officer

Thank you, Steve, and welcome, everyone, to our second quarter earnings call for 2022. I'm pleased to say Zoetis delivered another strong quarter with 8% operational growth in revenue and 9% operational growth in adjusted net income, driven once again by the strength of our companion animal portfolio. We saw a balanced performance across our segments with similar operational revenue growth for both the U.S. and international, 9% and 8%, respectively.

Our diversity and strength across parasiticides, dermatology products, vaccines, and monoclonal antibodies for pain continue to demonstrate people's desire for innovative and effective care for their pets. We continue to see positive spending trends across the globe for pet care. And we grew 14% operationally in our companion animal portfolio. As anticipated, our livestock portfolio continued to face challenges, declining 1% operationally in the second quarter, largely due to generic competition primarily in U.S.

cattle and declines in swine products in China due to lower pork prices and COVID-related supply constraints. Overall, our business remains strong, thanks to the durability of our global portfolio and a steady pipeline of new products. Even as we face uncertain macroeconomic conditions, continued supply constraints, generic competition, and the war in Ukraine, we remain confident in the resilience of our business and colleagues. As we look to the rest of the year, we are updating and narrowing our guidance to reflect our positive outlook for the remainder of 2022 and the negative impact of recent changes to foreign exchange rates.

Wetteny will walk you through the details in his remarks. As we look at the second half of the year, we remain confident in our long-term growth drivers and our ability to maintain a steady supply for customers despite inflationary pressures on the global economy and ongoing constraints for certain products. We all know pet owners love their dogs and cats and pet care remains a very positive and robust market, showing little impact from broader consumer concerns with inflation for the global economy. As we expected during the pandemic, that clinic visits are normalizing over time and spending continues to show strong growth based on the latest U.S.

numbers. The positive dynamic between pets and pet owners, which I've spoken about before, is proving sustainable and recession-resistant due to people's affinity for their pets, a willingness to prioritize medical care for their pets, and key demographic drivers such as the increased pet ownership by Gen Z and millennials and the greater percentage of high income households owning pets. Our innovative companion animal portfolio is well suited to address these customer needs. Our key dermatology products continue to demonstrate strong growth, 22% operationally for the first half, and we see opportunity to expand in underpenetrated markets especially internationally and introduce life cycle innovations like Apoquel chewable tablets.

We have more to come in the pipeline for dermatology, and we do not foresee any competitors for Apoquel or Cytopoint this year or in the first half of 2023. In terms of parasiticides, the Simparica franchise, including Simparica Trio, is performing extremely well. having grown 47% operationally through the first half of the year and is gaining share in the industry's largest category. We currently anticipate a competing triple-combination parasiticide to be approved in the U.S.

in the next 6 months with a possible launch next year. However, we believe Trio will continue to grow based on a strong label, proven efficacy, and the support of DTC marketing in the U.S. and international markets. Our monoclonal antibodies for pain, Librela, and Solensia, are performing very well in approved markets across Europe, and we remain very confident in the blockbuster potential of these breakthrough treatments.

In terms of the U.S., we have begun early experience trials for Solensia and expect a broader market launch in the fourth quarter. And we still anticipate approval for Librela later this year, assuming FDA inspections are completed at facilities outside the United States. Meanwhile, our operational growth in international has remained steady throughout the first half of the year at 8% despite COVID lockdowns in China and revenue reductions in Russia and Ukraine due to the war. Excluding the impact of Russia and Ukraine in the first half, our international sales would have grown 9% operationally.

This is the latest example of how our diverse portfolio and global footprint drive steady and sustainable growth for the business. While some markets may be experiencing setbacks in the quarter, other markets like the U.S., Australia, Southern Europe, and other emerging markets are driving our performance. In the second half, we see China returning to stronger growth if COVID stays in check, and we continue to expect the diversity across geographies and species to remain strong. In terms of livestock, we expect continued pressure from generic competition, primarily in U.S.

cattle and poultry products. However, we are generating growth across various livestock species in markets outside the U.S. and fish continues to perform exceptionally well. Finally, like many companies, we are managing through supply constraints this year with certain products.

We continue working hard to optimize our supply chain this year so we can meet the increasing demand for certain key products. Looking ahead, we will continue to invest in the resources, DTC marketing, and manufacturing capacity we need to support our future growth and achieve results for our customers and shareholders. We are advancing our driven-to-care sustainability goals that were established last year. And we published our 2021 progress update and ESG metrics in the second quarter, highlighting achievements toward our DE&I aspirations, expanded clinic goals, and support for the veterinary profession.

We are committed to staying on our journey to be the most sustainable animal health company in the world. We also continue to invest in R&D, business development, and new capabilities across the business to enhance our portfolio and ensure our long-term growth. In the second quarter, we continued to receive approvals for new products like pullback, Procerta-HVT-IBD-ND, expand key franchises like Apoquel into new markets and acquire new businesses to complement our portfolio such as Basepaws, a pet care genetics company. In closing, our business continues to perform extraordinarily well in one of the most dynamic markets I've ever seen.

Diversity, innovation, and customer focus are our cornerstones for excellence. I want to thank our colleagues for their tenacity, commitment, and resilience as we continue to deliver for our customers and shareholders. Thank you. Now let me hand things off to Wetteny.

Wetteny Joseph -- Chief Financial Officer

Thank you, Kristin, and good morning, everyone. As Kristin mentioned, we had a very strong quarter with growth across a number of our core franchises and the continued resilience of our end markets. Today, I will focus my comments on our second quarter financial performance, the key drivers contributing to our performance, and provide an update on our full year 2022 guidance. In the second quarter, we generated revenue of $2.1 billion, growing 5% on a reported basis and 8% on an operational basis.

Adjusted net income of $567 million was flat on a reported basis and grew 9% on an operational basis. Of the 8% operational revenue growth, 3% is from price and 5% from volume. Volume growth consisted of 6% from new products, which includes the Simparica Trio and Librela, 2% from key dermatology products, while other in-line products declined 3%. The decline in other inline products was expected and largely the result of the impact of intermittent supply challenges and generic competition for Draxxin.

Companion animal products continue to be the primary driver of growth, growing 14% operational with livestock declining 1% on an operational basis in the quarter. Simparica Trio was the largest contributor to growth in the quarter. Trio posted global revenue of $237 million, representing operational growth of 72% versus the comparable 2021 period. We also continue to experience better-than-expected results from Trio franchise outside the U.S.

where we had sales of almost $30 million. We expect to continue to grow the addressable market for flea, tick, and heartworm globally and see significant headroom for growth with brands like Simparica and Trio. Meanwhile, our key dermatology products, Apoquel and Cytopoint had significant global growth again with $315 million of revenue, representing 16% operational growth against a robust prior year in which these products were 22% operationally in the second quarter of 2021. In Europe, our monoclonal antibodies fostered pain in dogs and cats also meaningfully contributed to growth posting $31 million in sales.

Our global companion animal diagnostics portfolio recorded $83 million in revenue in Q2, declining 9% operationally. Growth in our international diagnostics portfolio was more than offset by a decline in our U.S. business in the quarter. In the U.S., we experienced a decrease in sales resulting from our new grocery market model and the build-out of a sizable and new dedicated field force for diagnostics.

While disruptive in the short term, this investment is putting the necessary fundamental elements in place to position and grow our diagnostics portfolio over the long run. We expect the effectiveness of our new diagnostic sales force to improve gradually for the remainder of the year. Diagnostics remains core to our business and a key long-term growth driver for Zoetis. Sales of life spa products declined 1% operationally in the quarter, negatively impacting growth across the portfolio were global generic competition for Draxxin and the war in Ukraine.

China swine products again declined due to lower pork prices and COVID-related lockdowns. Our U.S. poultry portfolio also continues to be challenged by generics and cheaper alternatives to Zoamix. Meanwhile, our fish portfolio again grew double digits in the quarter.

And along with the strength of our sheep products in Australia, partially offset the broader decline. Overall, livestock performance in the quarter continues to be in line with our expectations. Now moving on to revenue growth by segment for the quarter. U.S.

revenue was $1.1 billion in the quarter, growing 9% with companion animal products growing 13% and livestock sales declining 7%. Focusing first on companion animal. U.S. set practice revenue trends continue to be positive with practice revenue growing approximately 5%.

Spending per visit remained strong again this quarter, increasing over 7%. Visit declined more than 2%, primarily due to challenging prior year comparisons. In terms of best line traffic, it is worth noting that business in the second quarter were above the number of visits pre-covid in the second quarter of 2019 and the trend line for growth in visits over the last several years continues to slow favorably. I would also like to point out that our companion animal portfolio in the U.S.

had volume growth of 8% in the quarter. our injectable portfolio of products that must be administered in the vet clinic also saw volume growth in the quarter. These products include Cytopoint, vaccines, and Par. Underlying demand for veterinary care remains robust throughout the country even as people return to work.

While labor challenges do exist as they do across most industries, we believe that clinic revenue will continue to grow at levels above what we were seeing prior to COVID as the standard of veterinary care continues to increase through innovation, better demographics, higher compliance, and more pets. Companion animal growth of 13% in the U.S. was driven largely by sales from Simparica Trio as well as key dermatology products. Growth of Simparica Trio was again strong in the quarter with sales of $208 million in the U.S., growing 74%.

We are pleased to see that a significant number of Trio customers are new to the fleet tech and heartworm category altogether. In addition, we continue to meet our clinic penetration targets and take share within individual clinics. These dynamics will provide additional runway for future expansion of both the broader market and revenue growth for Trio. Key dermatology product sales were $219 million for the quarter, growing 11% with Apoquel and Cytopoint each significantly contributing to growth.

Year to date, our derm portfolio grew 16%. Our investments to support our derm portfolio have been instrumental in driving more patients into the clinics and we will continue to invest meaningfully in this space as a large portion of dogs with dermatitis remain undertreated, representing an opportunity to further expand the market. U.S. livestock declined 7% in the quarter, driven primarily by sales of cattle products as a result of generic competition for Draxxin.

Meanwhile, our poultry portfolio continues to be negatively impacted by the expanded use of lower-cost alternatives and generic competition for Zoamix. Swine products sales grew in the quarter as a result of increased disease prevalence and favorable market conditions for producers. Moving on to our international segment, where revenue grew 2% on a reported basis and 8% operationally in the quarter. Companion animal revenue grew 16% operationally and loss lag revenue grew 2% operationally.

Increased sales of companion animal products resulted from growth of modifying studies for alleviation of osteoarthritis pain, our key dermatology products and the Simparica franchise. These core brands continue to benefit from our international direct-to-consumer promotional campaigns and we remain excited with the long-term prospects of these programs. We continue to be pleased with the performance of our monocoantibodies for OA pain with Librela generating $26 million and Solensia delivering $5 million in second quarter sales. Librela remains on track to exceed $100 million in revenue this year.

As we have mentioned in prior quarters, Librela is the No. 1 pain product in the EU with the underlying performance metrics being very favorable for future growth. Reordering rates remain high. Compliance continues to exceed our initial expectations, and we continue to see significant opportunity to expand the pain market with a meaningful percentage of dogs on Librela being new to the market.

It is also worth noting that we are observing similar pet owner and best line trends in many of our key international markets that we are seeing in the U.S. The higher standard of care and better demographics as well as a more rapid adoption of innovation continues to expand our test for our products, and we expect these trends to continue. Volume growth in our international and companion animal portfolio was 10% in the second quarter, and we also saw growth across our injectable products, including monoclonal antibodies, vaccines, and Cytopoint. Meanwhile, international livestock grew 2% operationally in the quarter with solid growth across fish, cattle, and sheep.

Our fish portfolio experienced increased demand for vaccines in key salmon markets, including Chile and Norway. Cattle grew through favorable market conditions and price in key emerging markets, including Australia, Turkey, China and the U.K. sales of sheep products grew as a result of favorable market conditions and new product launches in Australia. Growth was partially offset by continued weakness with the price of pork and COVID-related supply challenges in China as well as unfavorable producer rotational programs with MFAs in Europe and reduced stock sizes in Latin America impacting poultry.

Now moving on to the rest of the P&L for the quarter. Adjusted gross margins of 69.8% decreased 120 basis points on a comparable basis to the prior year, resulting primarily from unfavorable foreign exchange impacts as well as higher manufacturing, freight, and other costs partially offset by favorable price and mix. Adjusted operating expense increased 10% operationally with SG&A growth of 8% operationally, driven by promotional and marketing expenses related to key brands and new product launches as well as T&E falls beginning to return to pre-COVID levels. R&D expenses increased 16% operationally due to higher compensation costs, increased spending on projects, and higher operating costs.

The adjusted tax rate for the quarter was 20.7%, an increase of 70 basis points, driven by changes in jurisdictional mix of earnings and lower discrete tax benefits related to share-based payments. And finally, adjusted net income grew 9% operationally and adjusted diluted EPS grew 10% operationally for the quarter. Capital expenditures in the second quarter were $146 million. We are still anticipating a significant increase in capex furnitures for the back half of 2022, primarily related to investments in Ireland, the U.S., and China to support manufacturing capacity needed to meet our long-term growth demands.

In the quarter, we returned over $600 million to shareholders through a combination of share repurchases and dividends. We repurchased only $450 million of Zoetis shares, representing our largest share repurchase ever. Now moving on to our updated guidance for the full year 2022. For operational revenue growth, we are maintaining the midpoint and narrowing the range of growth to 9.5% to 10.5%, previously 9% to 11%.

We are increasing our operational growth expectations for adjusted net income to a range of 11% to 13%, previously 10% to 13%. This change in guidance signals increased confidence in the back half of the year due to the continuing outperformance of companion animal, easing of certain supply constraints and an improvement in our business in China. Please note that our guidance for adjusted interest expense and/or ID was changed to reflect favorable changes to interest income. Foreign exchange rates on our updated guidance as of late July and reflect the continued strengthening of the U.S.

dollar. Beginning with revenue for the full year 2022 due to the narrowing of our range and the impact of foreign exchange, we are now projecting revenue of between $8.225 billion and $8.325 billion. We now expect adjusted net income to be in the range of $2.35 billion to $2.39 billion. And finally, we expect adjusted diluted EPS to be in the range of $4.97 to $5.05 and reported diluted EPS to be in the range of $4.65 to $4.75.

While guidance possess our outlook for the full year due to the unique factors impacting our business in 2022, I would like to note that our guidance for growth, especially for revenue and adjusted net income will be rated toward the end of the year. While we expect operating expenses to be incurred at a similar rate across that half of the year, we are noting an easier opex pop in Q4 than Q3 due to heavy spending in the fourth quarter of last year. Also, in Q3 of last year, we experienced an unusually low adjusted effective tax rate of 16.7% due to favorability related to foreign-derived intangible income and certain discrete items. We do not expect similar favorability this year.

Our full year 2022 guidance once again reflects our value proposition of growing revenue in line with or faster than the market and growing adjusted net income faster than revenue over the long term. Our success will continue to come from our diversified portfolio of enduring brands driven by multiple sources of in-line growth, productive innovation, and an infrastructure to develop and expand markets globally. We expect to continue to execute across multiple dimensions of our business and capitalize on favorable end market dynamics for the foreseeable future. Now I'll hand things over to the operator to open the line for your questions.

Operator?

Questions & Answers:

Operator

[Operator instructions] We'll take our first question from Michael Ryskin of Bank of America.

Michael Ryskin -- Bank of America Merrill Lynch -- Analyst

Great. Thanks for taking the question. I'm going to try to squeeze in two real quick. First, on the -- your comments on the Trio competition.

Kristin, certainly something that's been talked about and anticipated for a while. But I'm curious if you have any updated thoughts on how you'll respond? Is there going to be a change to how you price Simparica Trio or any additional promotional or do you see plants you can try to implement in the next six months. And I'm wondering if it's too early to give us maybe a ballpark dollar target for next year. Is it great to think that you could hit $1 billion in Trio sales in 2023.

And then a quick follow-up, if I can. On margins for the year, when I'm hoping you could -- can you walk us impact to margins, both on gross margin and opex. Just wondering how that factors into the updated outlook. Thanks.

Kristin Peck -- Chief Executive Officer

Sure. I'll take the first one, Mike. Thanks for the question. For starters, we were really pleased with performance of Simparica Trio and Simparica franchise in the quarter with 72% growth.

And we do expect even with competition to grow the franchise here. What we're really seeing in the market is a strong shift from topicals and collars to worlds. There's a new standard of care. So we see the category certainly growing.

We still believe we've got some number of advantages from being first to market. We've gotten a lot of customers enrolled in auto shift, which is really helping continue to drive growth there. We've got strong relationships with the large corporate. But importantly, on that issue, we still believe we've got significant room to expand in our penetrated clinics as we look at where our penetration within those clinics is.

The other thing is, we really don't believe you're going to see tons of switching without significant differentiation, which honestly we're not really expecting. This remains a significant market. And right now, the Simparica franchise is No. 2 in the U.S., and fleet ticket hard work.

So we are expecting approval of a potential competitor sometime in the back half of this year. and then obviously launching likely sometime next year. But we continue to believe that we can grow the franchise. We're going to invest highly in that through direct-to-consumer through our field force.

And we believe, given all the issues and opportunities we have, we can continue to grow this franchise.

Wetteny Joseph -- Chief Financial Officer

And Mike, your question on margins and opex. If you look at our gross margins on a year-to-date basis, if you take out the impact of FX, we're running about 20 basis points above last year. So in the quarter, you saw gross margins down about 120 basis points, but it's all FX driven. We've effectively maintained opex growth range in our guidance, and we're able to raise the bottom line guidance to 11% to 13% versus 10% to 13% that we started the year with.

So again, FX is having an impact here. but we are executing into our plan, and we'll see an improvement even on the bottom line roll rate.

Operator

Our next question comes from Erin Wright of Morgan Stanley.

Erin Wright -- Morgan Stanley -- Analyst

Great. Thanks. Could we get an update on Librela, both the U.S. approval and the supply taking straints for that product in international markets.

At this point, do you think you have visibility if supply chain constraints will have any sort of impact on the U.S. launch in terms of timing? And after you do get approval in the U.S., will you be ready to broadly launch that product immediately. And then just in terms of the guidance, how should we be thinking about what's embedded in the guidance for companion animal and livestock growth for the balance of the year? Are there any sort of dynamics from a quarter-to-quarter basis that we should be thinking about? Thanks.

Kristin Peck -- Chief Executive Officer

Great. Thanks, Erin. I'll take the first one, Wetteny can take that second question. We are really pleased so far in the Librela success outside of the U.S., and we'll talk a little bit what I think the implication, therefore, are within the U.S.

Right now, Librela is the No. 1 OA pain product in dogs in the EU already, which we think is outstanding if you look at its success, it's really been embraced and we see very strong reorder rates right now. Really impressively, 40% of dogs are new to the category, and we're seeing a 90% reorder rate. So we're really pleased.

This is a product, as you've noted, that does share some components with human COVID vaccines. And we've been managing that very carefully, making sure as we launch that we have adequate supply since this is a chronic medication. Really have been thoughtful about that. We do believe we've got additional capacity coming on in some of our suppliers as we look into the second half of this year and into next year.

So as we look at the rest of this year, we -- as we said, we believe this product will be a blockbuster this year, over $100 million. And we're very optimistic, assuming we get the approvals we're expecting an infection this year to be able to move exactly as we did it Solensia next year with an early experience in the first half followed by a full launch. So remain very excited investing heavily behind this and believe we're working really hard in the supply chain unless something changes dramatically, we are confident we will have the supply we need for a successful launch in the U.S. next year.

Wetteny Joseph -- Chief Financial Officer

Yes, Erin, with respect to our guidance and how you should be thinking about companion animal versus livestock. And so far year to date, we've delivered 9% operational growth at the top line, losses driven by companion animal. I think you can expect that to continue in the back half of the year when you consider, as Kristin just mentioned, Solensia will be fully launched in the second half in the U.S. here, we'll continue to see growth in Trio and with Librela, which we expect to be a blockbuster in the EU this year, we delivered $21 million in the first quarter, $26 million in the second quarter.

So that will continue to ramp. So I think those will contribute toward comparing that will continue to drive. When I think about livestock, we do see easier comps in the back half than we would have had in the first half to recall swine in China, for example, prices start to really decline in the second half of last year. So that becomes a comp when you think about Q3 and Q4.

And that, we did have some price adjustments in the fourth quarter last year on Draxxin leading into the start of the year. So those make for a slightly easier comp from a cattle perspective in the fourth quarter. So those are sort of the considerations, but I would expect the second half to look more like the first half in terms of the contribution from companion compared to livestock.

Operator

Our next question is from Jon Block of Stifel.

Jon Block -- Stifel Financial Corp. -- Analyst

Great guys. Thanks. Good morning. I'll try to ask two logos upfront.

Key derm, I think it was up 22% operationally in 1H, but I think it slowed from 27% in 1Q to 16% in 2Q, and I got a sort of a similar year ago comp. So can you talk to, Kristin, your thoughts on the topic term growth call it, just the trajectory going forward? Does the chewable version offer a price premium for you guys? And I think, Christian, you also talked about just no competition for maybe in the next 10 months, just how you have that line of sight. And then shifting to your second question to livestock. That market just always seems to be evolving.

Would love to get your thoughts on normalized growth returning to the industry in 2023, Kristin, I think you called it out last quarter. Does that stay intact? And would your growth be representative of market since I think you're going to get soon on the back end of some of the generic headwinds that you've been facing. Thanks, guys.

Kristin Peck -- Chief Executive Officer

Sure. Thanks so much, John. I'll take the first question, Wetteny takes the second one on livestock. We are very pleased with continued growth of derm.

To your point, in the first six months of the year, it grew 22% and -- in the quarter, it was 16%. There always has been some cyclicality, but we really believe we can continue to grow this franchise. We can expand it -- we have been through both branded and unbranded DTC. As you know, we just began this year really an investment in unbranded DTC in Europe, where we're now seeing significant pickup there.

We continue to see people home with pets more. And importantly, they are still in the U.S. alone, 6 million dogs who are still issuing who do not get -- have not received the product. So we think we can continue to grow this.

To your question on competition and life cycle innovation, we are investing heavily behind life cycle innovation. This is our category. As you saw last year, the franchise is already worth $1 billion. So we will work heavily to defend this, both with chewable and with other products in the pipeline.

Chewable is a real advantage for a lot of people who have trouble giving tools to their dogs and getting them to take it. I would say there may be a slight price depending it's very market specific as you look at the pricing there. But to us, it's really building the loyalty to our franchise overall. We don't have on the competition.

As you know, it's not a perfect science in our industry. But as you saw, we did on the compare to Trio sense that we do see competition. Mostly that is through working with chatter in the marketplace as well as with distributors and our large corporates, who start negotiating differently with us when they believe there's going to be competition in a space. So we are not seeing that in the same way that we are just starting to see that now on competition for our Simparica Trio franchise.

So we continue to believe we franchise with new innovation, with the strength of our commercial infrastructure with our investment in DTC. I'll let Wetteny take the second question on livestock.

Wetteny Joseph -- Chief Financial Officer

Yes. When you look at Life stock, historically, we've seen livestock grow around the 4% range. Certainly, you're very familiar with what's happened in the last few years in terms of -- and for us, with generic competition with Draxxin and Zoamix, the year is essentially executing as we expected on livestock. We continue to believe that we can see livestock returning to normalized growth in the 2023-2024 time frame.

And long term, when you look at livestock, we continue to see growth in this business long term, given population growth. We see urbanization as well as growing middle class, particularly as you look across emerging markets. And even this year, if you look at this quarter, for example, livestock grew 2% internationally, despite the headwinds in swine as I said, those comps get easier in the back half. And if you Russia-Ukraine, for example, another point there.

So we're seeing growth in emerging markets on livestock. We expect those to continue in long term with innovation as well as we continue our swine vaccines that we are launching vector vaccines on the poultry side, immunotherapies in cattle, etc., we would expect to continue to drive growth in livestock long term.

Operator

Our next question comes from Christine Rains of William Blair.

Christine Rains -- William Blair and Company -- Analyst

Hi. Yes. Thanks for the question. Just piggybacking off of that last point, can you further review those pipeline highlights in the work for our livestock portfolio.

And just related on the comparatively well international growth in livestock this quarter. Can you discuss the factors there that drive the different performance between international and domestic here? Thanks.

Wetteny Joseph -- Chief Financial Officer

Yes. Sure, I'd be happy to do that. Look, I think as we entered the year, we expected given the second year of generic competition for Draxxin, our largest product in cattle and to some extent, in swine as well. We expected that to drag our livestock performance in the U.S.

And again, that's essentially executing as we thought. What that is masking somewhat is the innovation that we are launching in swine for example, with vaccines in swine or vector vaccines that we have been launching will continue to drive in livestock as well. But we are seeing growth in emerging markets. You saw 2% growth in the quarter.

But again, that was offset partially with Russia-Ukraine impact here given the conflict there. as well as swine, as you know, from the second half of last year, we've seen a decrease in price that has impacted the performance there, although we have seen a lift in price on swine over the last number of weeks or months in China, we expect to continue as we execute through the second half of the year.

Kristin Peck -- Chief Executive Officer

Yes. I'll take a little bit more on your question on the pipeline and livestock. To build on what Wetteny saying, we do continue to believe that we're -- that there's significant growth opportunities in vaccines and livestock, that's what our customers are looking for. As Wetteny referenced, we've been launching some vaccines in swine.

Certainly, vector vaccines, we just announced approval of the second vector vaccine. In poultry, we'll be launching more vector vaccines, not poultry franchise as well. Really excited, as I mentioned earlier, about fish with 23% growth in the quarter. Apoquel really focusing on sea life and other potential vaccines there.

And then if you look at that more broadly as we look out a little farther investment immunotherapies as well as in precision livestock farming, continuing to add to our block yard product there to our genetics business there. So we do see a number of key platforms in livestock to drive innovation in the space. As Wetteny said, I think you can get back to the historical growth rates of around 4% as we hopefully lap some of these generic issues around Draxxin and Zoamix and poultry and the ASF issue in China. But I think to get above that, which we certainly aspire to do, it's going to take bringing innovation, and we are certainly investing to be the leader in innovation in livestock.

Operator

Our next question comes from Nathan Rich of Goldman Sachs.

Nathan Rich -- Goldman Sachs -- Analyst

Hi. Good morning. Thanks for the question. Kristin, you talked about the capacity and labor constraints that clinics are facing.

But I think you noted vaccines and injectable products continue to grow. I guess could you maybe talk to your ability to continue to grow those products the current market backdrop. And I guess, ultimately, the bigger picture question is, if we see these market dynamics, both from a macro standpoint as well as some of the pressures that Vetclinics are facing continue into next year. I guess, how should we think about growth? I guess, should we expect a similar level of companion animal growth as to what you're guiding to in the back half? Thank you.

Kristin Peck -- Chief Executive Officer

Sure. I think what's important to keep in mind is that vet clinics are doing quite well. If you look at growth in vet clinic revenue since 2019, it's up 20%. There's definitely with a 5% increase in the number of pets in the U.S.

There are capacity constraints to meeting all the needs. But I think what's important to remember also is we are not leveraged as high as some other businesses to in-clinic visits. A lot of our key products are chronic. So if you look at our derm portfolio, our Paris portfolio, etc., we're still seeing tremendous growth.

We had a 10% volume increase in the quarter in U.S. products. So I think it's important to think there's more movement to online and other spaces. So we don't see some of these capacity issues as a major issue for us in continuing to grow our business.

you're seeing some of the same capacity strength in Europe, and yet you're already seeing us have Librela looking to be a blockbuster product this year. And I think what really differentiates us is innovation. When there's important science and new products that they're excited about, we're still seeing great attention at the vet clinic for that and really driving that through. Although a lot of people are very focused on vet visits given we're not as leveraged to that.

we really think the spend per visit is really important. And I think we're leading in that category given innovation.

Operator

Our next question comes from Louise Chen of Cantor Fitzgerald.

Louise Chen -- Cantor Fitzgerald -- Analyst

Hi. Thank you for taking my question here. I'd like to ask you, are there any metrics that you can point to support price and demand elasticity in the pet health space? And then do you think about this the same way in livestock? Thank you.

Wetteny Joseph -- Chief Financial Officer

Well, I think certainly, when we look at price and demand, we've continued to see opportunistic price at or above inflation, and we've demonstrated that over the years, particularly in certain markets. We've also looked at data in terms of pet ownership and demographically, we see the structural improvement, I would say, even compared to a very strong basis to begin with. So if you look at pet ownership with respect to Gen Z and millennials, and they're prioritizing pet health that certainly bodes well. But also, we're seeing more adoption at higher income households if you look at what adoption numbers look like over the last number of years, which again is structurally very positive for the industry.

So as we've taken price over the years and we took about 5% price on -- in companion animal this year. Overall for the company, we've been running about 3% net given some of the last slight dynamics of the Draxxin generic competition. But we haven't been able to take price. And yet we still continue to see strong volume growth across the business.

And to Kristin's point, that's largely driven as well by innovation in the space. So we continue to see elasticity in terms of ability to take price at or above we see from an inflationary perspective.

Operator

Our next question comes from Elliot Wilbur of Raymond James.

Elliot Wilbur -- Raymond James -- Analyst

Thanks. Good morning. Just a follow-up question for Kristin around parasiticide trends in the quarter. Can you maybe just talk about category growth overall? It seemed like some of the metrics out there suggested that overall category growth had actually been down.

And obviously, Trio continues to perform extraordinarily well, particularly in the U.S. But I'm just thinking about the second half of the year and then early next year with a potential entrant, what you're seeing in terms of category growth? And if you could just give us the number in terms of where Simparica is with respect to overall share in the category. And if I could just get a quick follow-up in here on Librela. Obviously, the initial EU experience has been quite positive here.

I think you mentioned that 40% of pets were new to therapy. Just wanted to get maybe an update in terms of what you're seeing with respect to persistence some of the pets that started therapy initially and sort of where we what kind of persistence rates you're seeing sort of six to seven months after beginning therapy? And is that 40%, is that sort of a normal number in terms of new pets coming into the market? Or should the takeaway there be that Librela sort of test really kind of elevated the overall category growth? Thanks.

Kristin Peck -- Chief Executive Officer

Thanks, Elliot. I'll start with your Librela and see if maybe Wetteny can add anything on the Paris point. Really good questions there on Librela. If you look at the 40% new to the category, we do think that's extraordinary.

This is an established category. This isn't like derm when we started where it wasn't really a category. There have been many products across the globe for dogs, for pain management. But I think it really underscores the challenges with the existing therapies.

There's -- the trade-offs and safety and efficacy have been significant. Most of those therapies, you can't stay on for very long. And I think -- so for a lot of people that really didn't want to deal with some of those side effects that they had stayed out of the category. I think was something with the label that we have with a monoclonal antibody, we are clearly bringing new people to the sector, and we're growing that sector significantly.

I think we talked about before, the global market for pain for dogs was around $400 million. We believe with the addition of Librela that we can double the size of that market over time and move that to 800, and we think we can do that from a few ways and one of them you referenced. One is people staying on therapy longer. Certainly, with a safe and efficacious product, we believe we can increase days on therapy.

I think we can also be demonstrated with 40% increase the number of pets getting it. And third, we think we can grow the market certainly based on price. This is a premium product with significant innovation. So we are really pleased with the 40% growth.

It is certainly higher than even we were expecting with the new patients to the category. We are seeing significant -- probably higher than we were expected initially, compliant to the sense of months on therapy. So we remain extremely optimistic about EU and the persistence of this growth. And I'll let Wetteny take your follow-up question on Simparica.

Wetteny Joseph -- Chief Financial Officer

Yes. When we look at the category, broadly speaking, clearly, Trio grew 72% in the quarter. If you look at our overall Simparica franchise, grew 47%, right? So if you get Simparica, not Trio, but Simparica internationally, it grew 23% in the quarter. So we have the broadest offering in terms of parasiticides in the industry.

And clearly, the only triple combination in the U.S. What we are seeing is, categorically, we're seeing a shift from topicals and collars to all medications. And if you look at triple combination in the U.S. One of the interesting statistics that we've seen is that on Trio, about 30% of the dogs that are coming on Trio are new to the category and not having been prescribed a prescription of parasiticide in the prior 18 months or so.

So we do see significant room to continue to expand in this space. And as competitors come into the space, there'll be more DTC that will drive even more patients for the clinic, which is beneficial for us as well given our relationships across corporate accounts and so on will benefit from having more voices out driving more patients into the clinic. So we're not seeing a slowdown in the category. There is a bit of a shift from the topicals and collars into rolls and that benefits us given our premium products.

Operator

Our next question comes from Balaji Prasad of Barclays.

Balaji Prasad -- Barclays -- Analyst

Hi. Good morning and congratulations on the result. Two for me. Firstly, as we start to lap the impact of generics on Draxxin and Zoamix, would you still count a threat of generalization as a top two or top three challenge over the next two years? And if you could also add some broader comments around the percentage of your portfolio exposed to general completion of this period.

Also on diagnostics, operational decline of 9%, it seems to be the first quarter of decline after Q2 2020 and in contrast to your peer results. So wondering what kind of increased spend per visit did you notice that you've been calling out over the past few months? And any metrics that you can direct to between point of sale or reference labs that helps us understand this performance? Thank you.

Kristin Peck -- Chief Executive Officer

Sure. I'll start with your diagnostics and then I will let Wetteny do the Draxxin livestock question. As you look at -- we're about flat in the first half of the year in Diagnostics. And as Wetteny mentioned in his remarks, as you saw the decline, really, there was growth in international.

We made a huge investment in creating a stand-alone diagnostics field force and technical team and service team in the U.S. that is highly disruptive. As you know, if you watch other companies do this over time. So -- but we do believe in the absolute strength of this business long term, investing in it long term, as you've seen, we've invested in innovation and our images platform, etc., to grow this business.

So obviously, as that people get into new territories, etc., there's obviously some disruption that happens there. This honestly was anticipated. We remain extremely optimistic in the growth of this business and the strength of it. We certainly look at the strength of our international business and how well that's been doing and growing that with customers.

We invested in diagnostics for the long term and really believe we can drive strong growth here. And diagnostics as a sector is -- grows faster than the overall animal health space. And we believe we can bring disruptive innovation to the space to help us drive that. But I'll let Wetteny take the follow-up question on livestock and Draxxin.

Wetteny Joseph -- Chief Financial Officer

Yes, sure. If you look at Draxxin, right, the largest product that we have across our livestock portfolio. Beyond that, there isn't any other product that's even nearly that size and magnitude if you look across our portfolio as well in companion animals, there or products that are anywhere near any sort of LOE. So we would not anticipate after the first two years, that the generic competition element will be the key driver here in the business.

As we said, we expect livestock to be returning back to sort of normalized growth in the '23-'24 time frame is what we would expect in that regard to a genetic standpoint.

Operator

Our next question is from Chris Schott of J.P. Morgan.

Ekaterina Knyazkova -- J.P. Morgan -- Analyst

Hi. This is Ekaterina on from Chris from JPMorgan. Thanks for taking our question. And my question is on the macroeconomic environment here, are you seeing any notable differences when it comes to panel demand across geographies -- so Europe appears to be getting hit harder by some of the challenges related to fuel costs to food prices, and stuff like that.

And I was wondering if you're starting to see any changes in behavior in that market. Thank you.

Kristin Peck -- Chief Executive Officer

Sure. Thanks, Ekaterina. Good to have you on the call today. As you look at the sort of macroeconomics, we continue to see, on a global basis, very strong demand.

And I think what's driving that for us is the innovation that we bring to the market, as well as who's adopting some of these dogs, millennial Gen Z who are more willing to spend more on their pets as well as more of the pets being adopted by high-income families. That being said, Ekaterina, as you double-click into individual markets, you are seeing as economies get affected, obviously, overall demand may go down, but not -- we have so far not seen to do our products we are monitoring it carefully. I think the one place where we're starting to see a little more of that might be Latin America, just given some of the real hyperinflationary markets that you're starting to see there. But what we've really been pleased about in companion animal is the continued strength in willingness to spend and investing in innovative disruptive technology.

So there are certainly differences as you get into individual markets across the globe, but overall continued strong demand. And I would double-click for you since you asked the global question in a few places. One in Brazil, where we only printed about 1% growth in Q2 overall. Companion animals still grew 35% in the quarter, and you look at China, where we only had 3% growth, companion animal grew 24%.

So even in what many people might consider emerging markets, we are still seeing incredibly strong demand for our products and for our innovation.

Operator

And this does conclude our question-and-answer session for today. I'd be happy to return the call to our host for any concluding remarks.

Kristin Peck -- Chief Executive Officer

Great. Look, thank you, everyone, for your questions and for your continued interest in Zoetis. Just to summarize, we see continued strength across our diverse global portfolio, especially in our companion animal and pet care products. We are continuing to invest in talent and innovation and manufacturing expansions that can support our future growth.

And we are updating and narrowing our full year guidance to reflect a positive outlook for the remainder of 2022 and obviously, as many other companies, the negative impact of recent changes to foreign exchange rates. So I look forward to keeping you updated on future calls. Thanks so much. Have a great day.

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Steve Frank -- Vice President, Investor Relations

Kristin Peck -- Chief Executive Officer

Wetteny Joseph -- Chief Financial Officer

Michael Ryskin -- Bank of America Merrill Lynch -- Analyst

Erin Wright -- Morgan Stanley -- Analyst

Jon Block -- Stifel Financial Corp. -- Analyst

Christine Rains -- William Blair and Company -- Analyst

Nathan Rich -- Goldman Sachs -- Analyst

Louise Chen -- Cantor Fitzgerald -- Analyst

Elliot Wilbur -- Raymond James -- Analyst

Balaji Prasad -- Barclays -- Analyst

Ekaterina Knyazkova -- J.P. Morgan -- Analyst

More ZTS analysis

All earnings call transcripts